Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing

Executive Summary

Sandoz has used data extrapolation to all the indications for Roche's MabThera in its marketing submission for biosimilar rituximab, just accepted for review by the European Medicines Agency.


Related Content

First-Line Gazyva GALLIUM Success Bolsters Roche's CD20 Franchise
Tiny Mabion Races Big Pharma To EU Rituximab Market
Sandoz's Carol Lynch Highlights Decade Of Biosimilar Dominance And Plans For Many More Winning Years
Ten Years On, Access To Biosimilars Still Patchy in EU
Sandoz' Biosimilar Etanercept On Its Way To EU Market


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts